Abstract
We evaluated the impact of piperacillin/tazobactam (PT) therapy on galactomannan enzyme immunoassay (GEI) testing (Platelia; Bio-Rad, Marnes La Coquette, France). Galactomannan contents of PT batches were highly variable. We found that false-positive GEI results can be avoided by performance of blood sampling before PT administration and by using separate sites for blood sampling and for administration of antibiotics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antigens, Fungal / blood*
-
Aspergillosis / diagnosis*
-
False Positive Reactions
-
Galactose / analogs & derivatives
-
Humans
-
Immunoenzyme Techniques / methods
-
Mannans / blood*
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Piperacillin / therapeutic use*
-
Tazobactam
Substances
-
Antigens, Fungal
-
Mannans
-
galactomannan
-
Penicillanic Acid
-
Tazobactam
-
Piperacillin
-
Galactose